Rocket Pharma swings to Q2 FY26 net income of $123.2 million; R&D expenses fall 30.92% to $29.5 million

• Rocket Pharmaceuticals turned profitable in Q2 2026, posting net income of USD 123.2 million, versus a net loss of USD 68.9 million a year earlier.
• R&D expense fell 30.92% to USD 29.5 million, driven by lower manufacturing and development costs plus reduced stock-based compensation and headcount.
• G&A expense dropped 30.4% to USD 17.4 million, on lower commercial preparation spending, stock-based compensation, and legal costs.
• Other income climbed to USD 178.8 million on a net USD 178.2 million gain from selling a Priority Review Voucher, lifting cash to USD 283.7 million.
• All three initial RP-A501 Danon patients cleared the safety observation period with no TMA or capillary leak; cash runway forecast into Q2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608101600BIZWIRE_USPR_____20260810_BW430976) on August 10, 2026, and is solely responsible for the information contained therein.